Qiagen Share Price Nasdaq
Equities
NL0012169213
Biotechnology & Medical Research
Sales 2024 * | 2.01B 161B | Sales 2025 * | 2.14B 171B | Capitalization | 9.22B 736B |
---|---|---|---|---|---|
Net income 2024 * | 398M 31.78B | Net income 2025 * | 442M 35.3B | EV / Sales 2024 * | 4.74 x |
Net Debt 2024 * | 300M 23.98B | Net cash position 2025 * | 280M 22.37B | EV / Sales 2025 * | 4.17 x |
P/E ratio 2024 * |
23.5
x | P/E ratio 2025 * |
21
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.45% |
Latest transcript on Qiagen
Managers | Title | Age | Since |
---|---|---|---|
Thierry Bernard
CEO | Chief Executive Officer | 60 | 31/01/15 |
Metin Colpan
FOU | Founder | 69 | 28/04/96 |
Roland Sackers
DFI | Director of Finance/CFO | 56 | 31/12/98 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 74 | 31/05/11 | |
Metin Colpan
FOU | Founder | 69 | 28/04/96 |
Lawrence Rosen
CHM | Chairman | 66 | 25/06/13 |
1st Jan change | Capi. | |
---|---|---|
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |